Dendritic cell-targeted tumor antigen delivery by glucosylated lipid nanoparticles for precision tumor immunotherapy
Journal of Controlled Release · 2026-04 · 392 · 114671
DOI: 10.1016/j.jconrel.2026.114671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-04. Verfasst von Jing Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Department of Radiology, Huaxi MR Research Center (HMRRC), State Key Laboratory of Biotherapy, West China Hospital, and Colle…. Hauptthemen laut MEDLINE: Dendritic Cells, Immunotherapy, Antigens, Neoplasm, Nanoparticles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Sichuan Provincial Science and Technology Support Program, China Postdoctoral Science Foundation, Sichuan University.
Abstract (Originalsprache)
Vaccination is an important approach for cancer immunotherapy, but is limited by the inefficient delivery of immunogenic antigens to dendritic cells (DCs) to stimulate tumor-specific immune responses. Herein, we engineered glucosylated lipid nanoparticles (GluLNPs) to deliver tumor antigens and form personalized vaccines in situ, efficiently targeting DCs to stimulate robust antitumor immunity for the immunotherapy of low-immunogenic breast cancer. Through intratumoral injection, GluLNPs can efficiently capture and deliver tumor antigens, including neoantigens released from eradicated primary triple-negative breast tumors after mild phototherapy with photosensitizer-loaded nanoparticles (i.e., ICGNPs), to DCs, thereby triggering DC maturation and robust antitumor immune responses. Moreover, GluLNPs can effectively elicit strong systemic antitumor immunity against distant and metastatic triple-negative breast tumors when combined with immune checkpoint blockade. This study presents a practical strategy for developing effective DC-targeting personalized nanovaccines and in situ vaccination for precise and effective tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Department of Radiology, Huaxi MR Research Center (HMRRC), State Key Laboratory of Biotherapy, West China Hospital, and College of Polymer Science and Engineering, Sichuan University, Chengdu, Si…
- Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
- Department of Biotherapy, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Förderung
- Sichuan Provincial Science and Technology Support Program
- China Postdoctoral Science Foundation
- Sichuan University
- National Natural Science Foundation of China
Zitieren
APA
Liu, J., Lin, F., Hu, G., Zhang, R., Gong, C., Sun, X., & Mi, P. (2026). Dendritic cell-targeted tumor antigen delivery by glucosylated lipid nanoparticles for precision tumor immunotherapy. Journal of Controlled Release, 392, 114671. https://doi.org/10.1016/j.jconrel.2026.114671
Vancouver
Liu J, Lin F, Hu G, Zhang R, Gong C, Sun X, et al. Dendritic cell-targeted tumor antigen delivery by glucosylated lipid nanoparticles for precision tumor immunotherapy. Journal of Controlled Release. 2026;392:114671. doi:10.1016/j.jconrel.2026.114671
BibTeX
@article{Liu2026,
author = {Liu, Jing and Lin, Fengyi and Hu, Guanghao and Zhang, Ruixin and Gong, Changyang and Sun, Xun and Mi, Peng},
title = {Dendritic cell-targeted tumor antigen delivery by glucosylated lipid nanoparticles for precision tumor immunotherapy},
journal = {Journal of Controlled Release},
year = {2026},
volume = {392},
pages = {114671},
doi = {10.1016/j.jconrel.2026.114671}
}
EUVIMED